These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 3283766)

  • 1. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
    J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
    J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Monfette G; Emond J; Bergeron N
    Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
    Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R; Lachance R; Dupont A; Labrie F
    Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
    N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
    Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.
    Labrie F; Dupont A; Belanger A; Giguere M; Lacoursiere Y; Emond J; Monfette G; Bergeron V
    J Steroid Biochem; 1985 Nov; 23(5B):833-41. PubMed ID: 2934579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
    Labrie F; Dupont A; Cusan L; Manhès G; Bergeron N; Lacourcière Y; Pineault S; Bélanger A; Monfette G; Emond J
    J Steroid Biochem; 1989 Oct; 33(4B):817-21. PubMed ID: 2689788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J; Fischer M
    Wien Klin Wochenschr; 1988 Sep; 100(17):589-92. PubMed ID: 3055689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.